Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARLYSLE: Obecabtagene Autoleucel in Severe, Refractory SLE
NCT06333483Phase 1Active, not recruiting
- Sponsor
- Autolus Therapeutics plc
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of obecabtagene autoleucel in systemic lupus erythematosus (SLE), sponsored by Autolus Therapeutics plc. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse events at 12 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
obecabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06333483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333483.